|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Venook AP, Papandreou C, Furuse J and de
Guevara LL: The incidence and epidemiology of hepatocellular
carcinoma: A global and regional perspective. Oncologist. 15 Suppl
4:S5–S13. 2010. View Article : Google Scholar
|
|
4
|
Bialecki ES and Di Bisceglie AM: Diagnosis
of hepatocellular carcinoma. HPB Oxf. 7:26–34. 2005. View Article : Google Scholar
|
|
5
|
Lin S, Hoffmann K and Schemmer P:
Treatment of hepatocellular carcinoma: A systematic review. Liver
Cancer. 1:144–158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang B, Tang F, Wang Z, Qi G, Liang X, Li
B, Yuan S, Liu J, Yu S and He S: Overexpression of CTNND1 in
hepatocellular carcinoma promotes carcinous characters through
activation of Wnt/β-catenin signaling. J Exp Clin Cancer Res.
35:822016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu D, Liu JX, Endo T, Zhou H, Yao S,
Willert K, Schmidt-Wolf IG, Kipps TJ and Carson DA: Ethacrynic acid
exhibits selective toxicity to chronic lymphocytic leukemia cells
by inhibition of the Wnt/beta-catenin pathway. PLoS One.
4:e82942009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou H, Shen T, Luo Y, Liu L, Chen W, Xu
B, Han X, Pang J, Rivera CA and Huang S: The antitumor activity of
the fungicide ciclopirox. Int J Cancer. 127:2467–2477. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume
KG and Weissman IL: Use of a SCID mouse/human lymphoma model to
evaluate cytokine-induced killer cells with potent antitumor cell
activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sangiolo D: Cytokine induced killer cells
as promising immunotherapy for solid tumors. J Cancer. 2:363–368.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Technologies DM: Inc., . Cell Counting
Kit-8. Jan 24–2017http://www.dojindo.com/store/p/456-Cell-Counting-Kit-8.html
|
|
13
|
Schmidt M, Kim Y, Gast SM, Endo T, Lu D,
Carson D and Schmidt-Wolf IG: Increased in vivo efficacy of
lenalidomide and thalidomide by addition of ethacrynic acid. In
Vivo. 25:325–334. 2011.PubMed/NCBI
|
|
14
|
Vilchez V, Turcios L, Marti F and Gedaly
R: Targeting Wnt/β-catenin pathway in hepatocellular carcinoma
treatment. World J Gastroenterol. 22:823–832. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cieply B, Zeng G, Proverbs-Singh T, Geller
DA and Monga SP: Unique phenotype of hepatocellular cancers with
exon-3 mutations in beta-catenin gene. Hepatology. 49:821–831.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Von S, chulz-Hausmann SA, Schmeel LC,
Schmeel FC and Schmidt-Wolf IG: Targeting the Wnt/beta-catenin
pathway in renal cell carcinoma. Anticancer Res. 34:4101–4108.
2014.PubMed/NCBI
|
|
17
|
Schmeel LC, Schmeel FC, Kim Y, Endo T, Lu
D and Schmidt-Wolf IG: Targeting the Wnt/beta-catenin pathway in
multiple myeloma. Anticancer Res. 33:4719–4726. 2013.PubMed/NCBI
|
|
18
|
Weir SJ, Patton L, Castle K, Rajewski L,
Kasper J and Schimmer AD: The repositioning of the anti-fungal
agent ciclopirox olamine as a novel therapeutic agent for the
treatment of haematologic malignancy. J Clin Pharm Ther.
36:128–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M,
Leoni LM, Kipps TJ, Corr M and Carson DA: Activation of the Wnt
signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad
Sci USA. 101:3118–3123. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim Y, Alpmann P, Blaum-Feder S, Krämer S,
Endo T, Lu D, Carson D and Schmidt-Wolf IG: Increased in vivo
efficacy of lenalidomide by addition of piroctone olamine. In Vivo.
25:99–103. 2011.PubMed/NCBI
|
|
21
|
Kim Y, Alpmann P, Blaum-Feder S, Krämer S,
Endo T, Lu D, Carson D and Schmidt-Wolf IG: In vivo efficacy of
griseofulvin against multiple myeloma. Leuk Res. 35:1070–1073.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo Y and Han W: Cytokine-induced killer
(CIK) cells: From basic research to clinical translation. Chin J
Cancer. 34:99–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song S, Christova T, Perusini S, Alizadeh
S, Bao RY, Miller BW, Hurren R, Jitkova Y, Gronda M, Isaac M, et
al: Wnt inhibitor screen reveals iron dependence of β-catenin
signaling in cancers. Cancer Res. 71:7628–7639. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang X, Hao HX, Growney JD, Woolfenden S,
Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, et al:
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic
ductal adenocarcinoma. Proc Natl Acad Sci USA. 110:12649–12654.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bar-Yehuda S, Stemmer SM, Madi L, Castel
D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, Del Valle
L, et al: The A3 adenosine receptor agonist CF102 induces apoptosis
of hepatocellular carcinoma via de-regulation of the Wnt and
NF-kappaB signal transduction pathways. Int J Oncol. 33:287–295.
2008.PubMed/NCBI
|
|
26
|
Stemmer SM, Benjaminov O, Medalia G,
Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z,
Farbstein M, Cohen S, et al: CF102 for the treatment of
hepatocellular carcinoma: A phase I/II, open-label, dose-escalation
study. Oncologist. 18:25–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Human
Pathol. 40:1512–1515. 2009. View Article : Google Scholar
|
|
28
|
Buendia MA: Genetic alterations in
hepatoblastoma and hepatocellular carcinoma: Common and distinctive
aspects. Med Pediatr Oncol. 39:530–535. 2002. View Article : Google Scholar : PubMed/NCBI
|
